https://www.thebodypro.com/author/josep-m-llibre

Latest by Josep M. Llibre, M.D., Ph.D.

The Future of 2-Drug Regimens for People With HIV Img
Features

The Future of 2-Drug Regimens for People With HIV

Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. What can we expect in the future for two-drug regimens?

Tenofovir Alafenamide (TAF) Shows Better Safety Profile Than Old Tenofovir Img
Conference Coverage

Tenofovir Alafenamide (TAF) Shows Better Safety Profile Than Old Tenofovir

We may have finally seen the arrival of tenofovir alafenamide (TAF) at CROI 2015. The new formulation of tenofovir has demonstrated all that can be demonstrated at 48 weeks, in the phase-3 randomized, double-blind, double-dummy clinical trials GS104 ...

Pre-Exposure Prophylaxis (PrEP) Works: Implementing Science Into HIV Prevention Img
Conference Coverage

Pre-Exposure Prophylaxis (PrEP) Works: Implementing Science Into HIV Prevention

Results from three big HIV prevention trials were presented in one of the key sessions at CROI 2015. The French-Canadian IPERGAY study evaluated "on-demand" PrEP, which consisted of two pills of tenofovir/emtricitabine (Truvada), two to 24 hours pri...

A Tenofovir-Sparing Regimen Could Be a Safer Alternative for Starting Treatment Img
Conference Coverage

A Tenofovir-Sparing Regimen Could Be a Safer Alternative for Starting Treatment

The ACTG A5303 study at CROI 2015 was a double-blind, randomized trial that compared maraviroc (Selzentry, Celsentri), at 150 mg once daily, to tenofovir (TDF, Viread) in 259 treatment-naive patients, both arms with ritonavir (Norvir)-boosted darunav...

Curing Hepatitis C Virus in HIV-Coinfected Patients: Mission Accomplished Img
Conference Coverage

Curing Hepatitis C Virus in HIV-Coinfected Patients: Mission Accomplished

"Mission Accomplished," the title given by CROI 2015 organizers for the session on hepatitis C (HCV) treatment, was premonitional. Two big phase-3 studies in HIV/HCV coinfected individuals were presented. In the ION-4 study, 335 patients received tw...

Gene Therapy Overcomes Vaccines in HIV Prevention Img
Conference Coverage

Gene Therapy Overcomes Vaccines in HIV Prevention

For the HIV cure and eradication session at CROI 2015, once again, the organizers were funny in choosing the title, "Leaky Latency." In general, all reports were bad news for HIV cure. The more we learn, the higher the distance seems to HIV eradicati...

Conference Coverage

Switching to Stribild From Non-Nuke or Protease Inhibitor Regimens Works Well

So with all the positive news about integrase inhibitors in initial HIV treatment, is it safe to switch patients from other NNRTI (non-nucleoside reverse transcriptase inhibitor)- or PI (protease inhibitor)-based regimens to integrase inhibitor regim...

Conference Coverage

Raltegravir Superior to Boosted Protease Inhibitors as First-Line Treatment

U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...

Conference Coverage

Update on GSK744 and Monthly HIV Treatment or PrEP

For months, we've been excited about emerging data regarding GSK744 (also known as "744"), an investigational integrase inhibitor, close cousin of dolutegravir (Tivicay, DTG), with the potential for once-monthly injection dosing and promise in pre-ex...

Conference Coverage

Safer Sex Without a Condom: The PARTNER Study

Ever since the HPTN Study 052, we've concluded that having an undetectable HIV viral load strongly reduces the risk of HIV transmission. But how safe is condomless sex if one's viral load is undetectable? The PARTNER Study is an ongoing large Europe...